Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Keysight Technologies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Keysight Technologies Inc trades at $323.95 (market cap $55.04B). The key difference: Keysight Technologies Inc is the larger of the two by market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | KEYS | |
|---|---|---|
Market Cap | $39.89B | $55.04B |
Sector | Health | Technology |
52-Week High | $491.22 | $373.34 |
52-Week Low | $278.09 | $158.51 |
Enterprise Value | $38.15B | $55.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
KEYS trades at $322.05, down 0.04% on the day, with a bearish technical signal despite strong fundamentals. The company reported revenue of $5.38B in 2025 with net income of $850M, and has beaten EPS estimates for three consecutive quarters. Recent news highlights product launches in network cybersecurity and photonics design, supporting growth in AI and 5G markets.
Outlook remains positive with 75% analyst buy ratings and a $390.30 consensus price target, implying 21% upside. Key risks include high valuation multiples and volatile cash flows from significant investing activities. Earnings growth driven by technology demand presents the primary investment opportunity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
